Stay connected! Share and follow:

Leukaemia CARE Careline

We're here to talk | 24-hours a day

08088 010 444

FREE from landlines & most major mobile networks

SMC Approves New Myelofibrosis Drug – Ruxolitinib

written by

Leukaemia Care, Charity

  • SMC 2

It was announced today that the Scottish Medicines Consortium (SMC) has accepted ruxolitinib for use within NHS Scotland. Ruxolitinib is marketed by Novartis as Jakavi®.

Myelofibrosis is a myeloproliferative neoplasm (MPN) that affects the way blood cells are produced in the body. It can occur either as a disease on its own (primary myelofibrosis) or following on from polycythaemia vera or essential thrombocythaemia (secondary myelofibrosis). People over the age of 60 are most likely to have this disease, with men and women equally at risk. For further information on myelofibrosis, please click here.

The recommendation of the SMC following a full submission under the orphan process is that ruxolitinib is accepted for use within NHS Scotland for the treatment of disease-related splenomegaly (enlarged spleen) or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. A copy of the SMC advice is available here.

The SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ruxolitinib. The advice also takes account of the views from a Patient and Clinician Engagement (PACE) meeting, which was held with patient group representatives (including Leukaemia CARE) and clinical specialists to consider the added value of ruxolitinib, as an orphan medicine, in the context of NHS Scotland.

Monica Izmajlowicz, Chief Executive of Leukaemia CARE said: “We welcome this decision by the Scottish Medicines Consortium as significant progress in the treatment of myelofibrosis patients within NHS Scotland. We are delighted to see that the new PACE framework has again been effective in ensuring that patients who need it can access this treatment.”

If you are affected by this change and would like to speak to somebody about it, please call our CARE line on 08088 010 444.